Review of recent data in the uranium space:
Uranium spot price looking healthy overall. Will be interesting to see if the recent small pullback to 22.60 is seen again. RSI is looking strong but heading into overbought region which matches with the month end. Also, near the end of June MA50 crossed MA200. Looking set up for a big August imo.
Out of the main U players on the asx, July's main movers so far are:
PEN +18.37% resulting from the commencement of the US S232 Investigation into whether uranium imports are harming national security, a move that could lead to tariffsBOE -16% initiation of honeymoon restart. Technical break of 5 month support on chart
DYL 10.29% more positive drilling and Tumas resource expanded by 32%
VMY -10.47% completion of Alligator River Project acquisition, reduction in board fees and exec remuneration. Placement selling continues from Morgans.
Overall, recent broker data is showing that the pro STT traders are taking profits, which is typical of coming to an the end of a positive month for the spot price. I think the 2 unique stand out cases of data are for PDN and BKY. I wouldn't be surprised if BD starts to neaten up by the end of next week.
PDN +1.38% July
PEN +18.37% July
BMN 0% July
BKY 0% July
BOE -16% July
DYL +10.29% July
TOE -3.70% july
VMY -10.47%
- Forums
- Commodities
- URANIUM
- Uranium, like buying oil at $20 a barrel
Uranium, like buying oil at $20 a barrel, page-115
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add URANIUM (NYMEX) to my watchlist
(20min delay)
|
|||||
Last
$24.70 |
Change
0.250(1.02%) |
Mkt cap ! n/a |
Open | High | Low |
$24.70 | $0.00 | $0.00 |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug